NASDAQ:SPRC SciSparc (SPRC) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free SPRC Stock Alerts $1.26 +0.05 (+4.13%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$1.20▼$1.2850-Day Range$1.21▼$4.1752-Week Range$1.15▼$23.66Volume129,791 shsAverage Volume1.06 million shsMarket Capitalization$894,600.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get SciSparc alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About SciSparc Stock (NASDAQ:SPRC)SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and epilepsy and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation, as well as a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. The company was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.Read More SPRC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRC Stock News HeadlinesApril 15, 2024 | americanbankingnews.comSciSparc Ltd. (NASDAQ:SPRC) Short Interest UpdateApril 13, 2024 | investing.comSciSparc to acquire AutoMax in strategic mergerApril 25, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 11, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc to Acquire AutoMaxApril 11, 2024 | msn.comSciSparc to acquire vehicle importer AutoMaxApril 11, 2024 | msn.comSciSparc To Acquire AutoMax, A Strategic Leap Towards Industry DiversificationApril 11, 2024 | globenewswire.comSciSparc to Acquire AutoMaxMarch 27, 2024 | globenewswire.comSciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionApril 25, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 23, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchMarch 21, 2024 | globenewswire.comSciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer ResearchMarch 18, 2024 | globenewswire.comSciSparc Granted Another Patent, Strengthening its Core Technology in CanadaMarch 14, 2024 | investing.comSciSparc's venture MitoCareX Bio advances AI model for cancer drug discoveryMarch 14, 2024 | globenewswire.comSciSparc Achieves Major Milestone with First Patient Dosed in Autism Spectrum Disorder Clinical TrialMarch 12, 2024 | globenewswire.comSciSparc: MitoCareX Reveals Promising Results with Discovery of Novel Anti-Cancer Small Molecule StructureMarch 8, 2024 | msn.comAutism CBD Trial Enrolls Children: This Israeli Co. Is Making Headway In New TreatmentsMarch 8, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderMarch 8, 2024 | globenewswire.comSciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum DisorderMarch 7, 2024 | finanznachrichten.deSciSparc Ltd: SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyMarch 7, 2024 | globenewswire.comSciSparc Granted Patent for Core Technology in Multiple Jurisdictions in EuropeMarch 6, 2024 | globenewswire.comSciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management TechnologyFebruary 29, 2024 | globenewswire.comSciSparc Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of DosingFebruary 27, 2024 | msn.comSciSparc gains as Clearmind partnership yields 3 new international patent applicationsFebruary 27, 2024 | globenewswire.comSciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine CompoundsFebruary 21, 2024 | msn.comSciSparc shares up on patents filed for psychedelic compounds with ClearmindFebruary 20, 2024 | globenewswire.comSciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based CompoundsFebruary 1, 2024 | benzinga.comSciSparc Stock (NASDAQ:SPRC), Analyst Ratings, Price Targets, PredictionsSee More Headlines Receive SPRC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SciSparc and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/25/2024Next Earnings (Estimated)7/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SPRC CUSIPN/A CIK1611746 Webscisparc.com Phone972-3717-5777FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.10 Quick Ratio3.63 Sales & Book Value Annual Sales$2.88 million Price / Sales0.31 Cash FlowN/A Price / Cash FlowN/A Book Value$13.57 per share Price / Book0.09Miscellaneous Outstanding Shares710,000Free Float696,000Market Cap$894,600.00 OptionableNot Optionable Beta0.71 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Oz Adler CPA (Age 37)CEO & CFO Comp: $363kMr. Itschak Shrem (Age 77)President & Director Comp: $219kDr. Adi Zuloff-Shani Ph.D. (Age 55)Chief Technologies Officer Comp: $274kKey CompetitorsEvofem BiosciencesNASDAQ:EVFMEvelo BiosciencesNASDAQ:EVLOBellerophon TherapeuticsNASDAQ:BLPHBiodexa PharmaceuticalsNASDAQ:BDRXAditxtNASDAQ:ADTXView All Competitors SPRC Stock Analysis - Frequently Asked Questions How have SPRC shares performed in 2024? SciSparc's stock was trading at $4.88 at the start of the year. Since then, SPRC stock has decreased by 74.2% and is now trading at $1.26. View the best growth stocks for 2024 here. Are investors shorting SciSparc? SciSparc saw a increase in short interest in April. As of April 15th, there was short interest totaling 523,900 shares, an increase of 207.1% from the March 31st total of 170,600 shares. Based on an average trading volume of 1,290,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 21.4% of the shares of the stock are short sold. View SciSparc's Short Interest. When is SciSparc's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 1st 2024. View our SPRC earnings forecast. When did SciSparc's stock split? SciSparc shares reverse split before market open on Thursday, September 28th 2023. The 1-26 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of SciSparc? Shares of SPRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SPRC) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SciSparc Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
